ResMed Inc. NYSE:RMD isn't just selling plastic masks; it's trying to own the bedroom. With roughly 1 billion people worldwide choking for air in their sleep, the market is vast and mostly untapped. Management is shifting from a hardware-first mindset to a digital ecosystem where your ring, your watch, and your CPAP machine all talk to each other. It's a high-margin game of adherence, and right now, the company is the one setting the rules. While the hardware keeps patients breathing, the software keeps them paying, creating a sticky, recurring revenue model that is difficult for rivals to break.
Potential Bull Cases
1. A Massive Underpenetrated Market Meets a New Wave of Awareness
The core business sits on a mountain of unmet demand. With 1 billion people estimated to have sleep apnea and hundreds of millions more suffering from insomnia and chronic obstructive pulmonary disease, the company has only scratched the surface. Awareness used to be the biggest hurdle, but big tech and big pharma are now doing the heavy lifting. Wearables from Apple, Samsung, and Oura are putting sleep data on every wrist and finger, while the rise of weight-loss drugs is actually driving more people into doctors' offices for screening. This surge in awareness funnels new patients toward the company's gold-standard therapy at a time when diagnosis rates remain remarkably low.
2. High-Tech Fabric and Software Create a Sticky Ecosystem
Management has successfully changed the basis of competition from simple plastic masks to advanced fabric technology and artificial intelligence. New fabric-based masks, like the AirTouch N30i, have driven 90-day compliance rates 6% higher than traditional silicone versions. This matters because adherence is the single biggest driver of lifetime value for the business. When patients stay on therapy, they keep buying masks and filters, and they stay connected to the AirView software platform. The company's new generative artificial intelligence sleep coach has already handled 1.5 million inquiries, which helps patients troubleshoot without needing to call customer support, lowering the cost to serve while keeping users loyal.
3. The Noctrix Acquisition Opens a New Front in Sleep Health
By acquiring Noctrix Health in June 2026, the company expanded its reach into restless leg syndrome, the third most prevalent sleep disorder. This is a classic operator move: buy a first-in-class wearable therapeutic and plug it into an existing global distribution machine. Roughly 17 million people in the U.S. alone suffer from the condition, and the prescriptions are written by the same sleep physicians who already know the company's sales reps. Because the device flows through the same home medical equipment channels the company leads in market share, it can scale this new business with minimal incremental sales cost, creating a high-margin growth engine outside of its core breathing products.
4. Supply Chain Productivity Is Driving Record Profitability
Management expanded the non-GAAP gross margin by 240 basis points to 62.4% in fiscal year 2026. This expansion didn't happen by accident; it was the result of a multiyear effort to automate manufacturing and optimize the global distribution network. The company is currently investing between $160 million to $180 million in capital expenditures to further automate its footprint. These efficiencies more than offset the sting of inflation and higher freight costs. By driving unit costs down while maintaining premium pricing, the company generated $1.6 billion in free cash flow in fiscal year 2026, providing the fuel needed to out-invest competitors in research and development for the next generation of devices.
5. Aggressive Capital Returns Signal Management Confidence
The company is putting its cash to work for shareholders at an accelerating pace. For fiscal year 2027, management plans to return over $1.85 billion through dividends and share repurchases, a 75% increase over the previous year. This includes a 10% hike to the quarterly dividend and a $450 million accelerated share repurchase program funded by the expected divestiture of its noncore MatrixCare business. This aggressive capital allocation strategy suggests management believes the stock is undervalued and that the core business can generate massive cash flow even while funding new growth. It's a clear signal that the company has moved past its pandemic-era supply chain struggles and is back in offensive mode.
Potential Bear Cases
1. The Astral Recall Is a Costly Operational Stumble
Even the best operators hit a wall sometimes, and the field safety notification for Astral devices is a significant hurdle. The company took a $42 million provision in the fourth quarter of fiscal year 2026 to cover the costs of this recall. More importantly, management has suspended all sales of new Astral ventilators for fiscal year 2027 to focus parts and service on existing patients. This decision creates a $75 million revenue headwind and a 15 cent drag on earnings per share. While the company is prioritizing patient safety, the pause in sales gives competitors an opening to gain market share in the high-acuity life support market that may be difficult to win back later.
2. Persistent Inflation Puts Pressure on Hard-Won Margins
The company's gross margin expansion is facing a stiff headwind from the rising costs of electronic components and global freight. In the fourth quarter of fiscal year 2026, the gross margin actually dipped 50 basis points sequentially from the third quarter. Management is attempting to counter this by pushing through modest price increases across 140 countries, but there is a limit to how much its customers can bear. Many home medical equipment providers operate on tight, fixed reimbursement rates from insurers. If these providers can't pass on the costs, they may push back on the company's pricing or seek out cheaper, generic alternatives for masks and accessories, threatening the company's premium margin profile.
3. The Long-Term GLP-1 Impact Remains an Unsolved Variable
While the company points to data showing that weight-loss drugs drive more patients into the sleep apnea funnel, the long-term risk to the total addressable market is still real. If GLP-1 medications become widely available and affordable, a significant portion of the patient population could lose enough weight to potentially resolve their obstructive sleep apnea entirely. Management's own analysis shows that patients on these drugs are currently more adherent to CPAP therapy, but that may be a temporary correlation. If the root cause of sleep apnea is addressed through medication for a large enough cohort, the lifelong demand for masks and machines could shrink, forcing the company to find new ways to replace that lost recurring revenue.
The Moneyball Verdict: 85 out of 100
Our proprietary Moneyball scoring system assigns ResMed an overall Superscore of 85 out of 100, placing it in the Strong category. The Superscore is an AI-powered score that evaluates a company's overall strength by combining financial performance, product market position, technological capabilities, leadership quality, and relative valuation. It represents the unification of all our scores into a single score for public companies, with five rating bands: Exceptional (90-100), Strong (75-89), Above Average (60-74), Average (40-59), and Cautious (0-39). This score places the company in the Top ~3% of all companies we score, or ahead of roughly 97 out of every 100 companies in our database.
This Strong score for ResMed reinforces the case for its sticky digital ecosystem, where software adherence drives long-term value. While product recalls and inflation create temporary friction, the company's ability to turn hardware users into recurring software subscribers creates a structural advantage. Its operational efficiency and dominant market position outweigh the manageable headwinds from manufacturing stumbles, pricing pressure, and weight-loss drug fears.